Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963090 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance Foundation Trials.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02963090 is a Phase 2 study that was terminated before completion, run by Alliance Foundation Trials. The registered enrollment target is 9 participants.
The verdict
NCT02963090, a Phase 2 study, was terminated before completion, sponsored by Alliance Foundation Trials.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a multi-institutional, randomized, open-label phase II study of pembrolizumab compared to topotecan, administered to patients with SCLC who have progressed or relapsed after first-line treatment with etoposide and platinum. Patients will be randomized in a 2:1 fashion to receive pembrolizumab or topotecan. Participants in the topotecan arm that progress will be allowed to cross-over to the pembrolizumab arm.
Interventions
- DRUG Pembrolizumab
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-05-20 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02963090
The ClinicalTrials.gov registry entry for NCT02963090 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02963090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02963090 about?
NCT02963090 is a clinical study titled "Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer". This is a multi-institutional, randomized, open-label phase II study of pembrolizumab compared to topotecan, administered to patients with SCLC who have progressed or relapsed after first-line treatment with etoposide and platinum. Patients will be randomized in a 2:1 fashion to receive pembrolizuma...
What is the current status of trial NCT02963090?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-05-20. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT02963090?
The interventions under investigation include: Pembrolizumab (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT02963090?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.